Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Shares Issued
Ratios

Benitec Biopharma (BNTC) Cost of Revenue (2019 - 2024)

Benitec Biopharma (BNTC) has disclosed Cost of Revenue for 6 consecutive years, with $3000.0 as the latest value for Q1 2024.

  • Quarterly Cost of Revenue changed N/A to $3000.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $3000.0 through Dec 2024, down 97.2% year-over-year, with the annual reading at $108000.0 for FY2024, N/A changed from the prior year.
  • Cost of Revenue hit $3000.0 in Q1 2024 for Benitec Biopharma, up from $1000.0 in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $134000.0 in Q3 2020 to a low of -$48000.0 in Q2 2020.
  • Historically, Cost of Revenue has averaged $27900.0 across 5 years, with a median of $8000.0 in 2021.
  • Biggest five-year swings in Cost of Revenue: plummeted 93.79% in 2020 and later skyrocketed 800.0% in 2022.
  • Year by year, Cost of Revenue stood at $19000.0 in 2020, then tumbled by 94.74% to $1000.0 in 2021, then surged by 800.0% to $9000.0 in 2022, then tumbled by 88.89% to $1000.0 in 2023, then surged by 200.0% to $3000.0 in 2024.
  • Business Quant data shows Cost of Revenue for BNTC at $3000.0 in Q1 2024, $1000.0 in Q4 2023, and $106000.0 in Q3 2023.